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Introduction: The aim of this study was to investigate whether 14-3-3η, a specific isoform of a family of proteins
regulating processes such as cellular signalling, activates cell-signalling pathways and induces factors known to
contribute to the pathophysiology of rheumatoid arthritis (RA). We also investigated whether 14-3-3η is associated
with more severe disease in both early and established RA.
Methods: We investigated the effect of 14-3-3η on the activation of RA-relevant signalling cascades and induction of
proinflammatory mediators that contribute to the joint damage process. 14-3-3η titres from 33 patients with early RA
(mean RA duration = 1.8 months) and from 40 patients with established RA were measured in serum drawn at the
3-year time point of the Behandel Strategieën study. The relationship between 14-3-3η titres and standard clinical
variables was investigated by correlation analysis. The association with radiographic damage and radiographic
progression over at least a 2-year period was investigated using univariate and multivariate regression analyses.
Results: 14-3-3η activated selected members of the mitogen-activated protein kinase (MAPK) family, mainly extracellular
regulated kinase 1/2 and c-Jun kinase, but not p38MAPK. Activation by 14-3-3η, using levels spanning the concentration
range found in RA patient serum, resulted in the induction of inflammatory transcripts such as interleukin 1 (IL-1) and
IL-6 and factors linked to the joint damage process, such as receptor activator of nuclear factor κB ligand and matrix
metalloproteinase 1. Serum 14-3-3η correlated significantly with rheumatoid factor (RF) (r = 0.43) and anticitrullinated
protein antibodies (ACPAs) (r = 0.31) in the early RA cohort, but not with C-reactive protein (CRP) or the Disease
Activity Score in 28 joints in either cohort. Serum 14-3-3η concentrations were significantly higher in patients with
radiographically assessed joint damage and in those who had radiographic progression. By multivariate analysis, we
show that 14-3-3η complemented markers such as CRP, RF and ACPA in informing RA radiographic status and/or
progression.
Conclusions: Extracellular 14-3-3η activates key signalling cascades and induces factors associated with the
pathogenesis of RA at concentrations found in patients with RA, and its expression is higher in patients with
radiographic damage and RA progression.* Correspondence: walter.maksymowych@ualberta.ca
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Rheumatoid arthritis (RA) is a chronic autoimmune
disease characterised by inflammation of the synovium
[1]. When left untreated, RA typically leads to severe
joint destruction [2]. Early diagnosis, combined with an
accurate prognostic assessment at presentation, is a cen-
tral tenet in the effective management of RA patients
[3]. There is consensus amongst rheumatologists that
the development of a risk stratification strategy to group
patients into low-, medium- and high-risk categories for
radiographic progression at presentation is a clinical
imperative [4]. Currently, this remains a major limitation
in patient management because risk factors such as
rheumatoid factor (RF), anticitrullinated protein anti-
bodies (ACPAs; often detected by performing an anti–
cyclic citrullinated peptide antibody test) and C-reactive
protein (CRP) together account for only 32% of the total
variance in predicting joint destruction, leaving 68% of
the variance unaccounted for [4].
Serum 14-3-3η, which was first described in 2007 [5]
as being elevated in arthritis, has been reported to be
significantly higher in RA patients than in healthy indi-
viduals and in various disease controls including, but
not limited to, osteoarthritis (OA), ankylosing spondylitis
(AS) and gout [6,7]. On the basis of receiver operating
characteristic curve analyses defining optimal sensitivity
and specificity, serum 14-3-3η positivity is denoted by a
concentration ≥0.19 ng/ml [6,7]. We have previously
shown that (1) serum 14-3-3η expression is not strongly
correlated with standard clinical and serological mea-
sures, is detected in both early and established RA, with
sensitivities of 60% to 82% and 78%, respectively, and (2)
that 14-3-3η positivity adds incrementally to both RF
and ACPA positivity for diagnostic sensitivity [8]. In a
previous study of an early RA cohort, we reported that
60% of patients were positive for 14-3-3η, 32% for RF,
44% for ACPA and 72% for at least one of those three
markers [8].
The 14-3-3 family of conserved regulatory proteins
consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ.
Under normal circumstances, these proteins exist as
intracellular adapters that can either homo- or hetero-
dimerise to form a cuplike structure known as the
amphipathic groove, which allows them to interact with
more than 200 intracellular proteins to modulate their
activities. Interactions include an array of biological pro-
cesses, such as protein trafficking and cellular signalling.
Externalisation of 14-3-3η, similarly to its process in RA
[5], is believed to be mediated in part through an exoso-
mal process in a like that of other intracellular proteins,
such as the release of heat shock proteins (HSPs) from
human peripheral blood mononuclear cells (PBMCs) or
B lymphocytes under heat stress [9,10]. Importantly,
these two families of proteins—14-3-3 and HSPs—havebeen described as key components of exosomal microve-
sicles [11], and it is now widely accepted that members
of the HSP superfamily, such as HSP60, behave as proin-
flammatory factors priming the immune system to re-
spond to a noxious agent [12].
In 2007, we reported a strong correlation between
the expression of 14-3-3η and matrix metalloproteinases
(MMPs) and demonstrated that extracellular 14-3-3η
possesses MMP-1-inducing activity in vitro on the basis
of 14-3-3η levels at the upper range of serum levels ob-
served in a small subset of RA patients [5-7]. MMPs are
serine proteases that play a critical role in maintaining
tissue homeostasis, but, in the context of RA, the im-
balance between expression of these proteolytic enzymes
and their cognate inhibitors leads to the breakdown of
cartilage [13].
MMP expression has been reported to be regulated
through the transcription factor activator protein 1 (AP-1),
which resides downstream from intracellular signalling
factors such as mitogen-activated protein kinase (MAPK)
[14-17]. The MAPK family, which includes extracellular
regulated kinase (ERK), c-Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK) and p38MAPK, has
been investigated extensively in RA [18]. Recently, de
Launay et al. reported a specific increase in ERK and JNK
activation, but not in p38MAPK activation, in early RA
patients with progressive joint destruction, underscoring
their possible relevance to the aetiology of RA [19].
In our present study, given the strong correlation of
14-3-3η with MMP-1 and MMP-3 in synovial fluid and
serum [5], we sought to advance the understanding of
the role of 14-3-3η in RA by assessing whether 14-3-3η
(1) possesses extracellular ligand properties leading to
activation of MAPK, (2) induces mediators of inflamma-
tion and joint destruction and (3) contributes prognostic
information in addition to clinical and serological mea-
sures used in the management of RA.
Methods
14-3-3η effects on cell signalling and induction of
pro-inflammatory mediators
To examine whether 14-3-3η possesses extracellular lig-
and properties relevant to RA, we investigated its effects
on the activation of RA-relevant signalling cascades and
the induction of proinflammatory mediators that con-
tribute to the joint damage process.
Low-endotoxin human recombinant 14-3-3η (Augurex
Life Sciences Corp, North Vancouver, BC, Canada) and
human recombinant tumour necrosis factor α (TNFα)
from (R&D Systems, Minneapolis, MN, USA) were used
for cell stimulation. 14-3-3η and TNFα were diluted using
serum-free media whereby 5 μl of the 14-3-3η or TNFα
stock were added to each millilitre of medium in wells to
achieve the concentration used for cell stimulation dosing.
Maksymowych et al. Arthritis Research & Therapy 2014, 16:R99 Page 3 of 11
http://arthritis-research.com/content/16/2/R99A dose selection study (0 to 100 ng/ml), coupled with a
15-minute cell stimulation experiment, was performed to
select the doses and time points for assessment of cell
signalling pathways, which were analysed by immunoblot-
ting with a phosphotyrosine antibody. On the basis of the
results of this study, we determined that, for cell signalling
experiments, a minimum dose of 12.5 ng/ml 14-3-3η and
TNFα would be used in order to observe a visibly de-
tectable difference in phosphorylation status above the un-
stimulated control. This dose of extracellular 14-3-3η
reflects concentrations observed in patient sera (0.0
to >20.0 ng/ml). Kilani et al. [5] reported that 14-3-3η
expression detected by Western blot analysis was three to
five times higher in synovial fluid than in matched patient
serum, supporting the 12.5 ng/ml cell stimulation dose
as being consistent with the concentration of 14-3-3η
present in the joint. For transcriptional studies of proin-
flammatory mediators, we analysed the impact of a range
of 14-3-3η concentrations comparable to those detected
in RA patient serum (0.1 to 100 ng/ml) and found that
they were well within the range found in synovial fluid.Cell culture
Monocyte lineage THP-1 cells were selected to investi-
gate the stimulatory effects of 14-3-3η, as this cell line
has been used extensively in the field because of the
importance of this lineage of cells in the pathogenesis of
RA [20]. Briefly, THP-1 cells were cultured in RPMI
1640 medium supplemented with 10% foetal bovine
serum in a humidified chamber at 37°C in a 5% CO2
atmosphere. Prior to being seeded, cells were centrifuged
for 5 minutes at 2,000 rpm. The cell pellet was then
washed once gently with serum-free medium, centri-
fuged and resuspended to 1 × 106 cells/ml.Activation of cell signalling pathways
To determine which cell signalling pathways are specific-
ally activated by 14-3-3η, the THP-1 cells were seeded at
a density of 2 × 106 cells per well and deprived of serum
for 6 hours prior to cell stimulation. Following cell star-
vation, the cells were stimulated with 12.5 ng/ml of lig-
and (14-3-3η or TNFα) up to 30 minutes. Cells were
harvested and lysed, and the phosphorylation status of
MAPK family members, specifically ERK, JNK/SAPK
and p38MAPK, were evaluated using phosphorylated
MAPK and the corresponding pan-antibodies (Cell
Signaling Technology, Beverly, MA, USA). Changes in
phosphorylation status were measured by densitometry
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA). Total protein levels were used as a
background control to ensure that changes were due to
increases in phosphorylation status rather than to in-
creases in the respective kinases.Expression of proinflammatory mediators
Induction of mediators of inflammation and destruction
by a range of concentrations of 14-3-3η (0.1 to 100 ng/ml)
were evaluated by mRNA analysis for interleukin 1β
(IL-1β), IL-6, MMP-1, MMP-9, receptor activator of nu-
clear factor κB ligand (RANKL) and TNFα. THP-1 cells
were resuspended in medium containing 0.1% foetal bo-
vine serum, seeded at a density of 2 × 106 cells per well
into a six-well dish and allowed to stand for 2 hours. The
cells were then stimulated with 14-3-3η (0.1 to 100 ng/ml)
or TNFα (50 ng/ml) for 18 hours using 5 μl of ligand per
millilitre of culture medium added to each well. The
reaction was terminated by the addition of ice-cold
phosphate-buffered saline, and then the cells were centri-
fuged. Following centrifugation, RNA was extracted from
the cell pellets using the illustra RNAspin Mini RNA
Isolation Kit (GE Healthcare Life Sciences, Pittsburgh, PA,
USA). The cDNA was synthesised from purified total
RNA using the RevertAid™ H Minus First Strand cDNA
Synthesis Kit (Thermo Scientific, Pittsburgh, PA, USA).
The PCR conditions for each primer were optimised inde-
pendently. Primers for RT-PCR analyses were produced
either by Augurex Life Sciences Corp or purchased from
R&D Systems. The levels of the housekeeping gene
GAPDH were evaluated to ensure that equal amounts of
cDNA were used for all samples.
Rheumatoid arthritis cohorts
Cohort A
Cohort A comprised 33 patients with RA (defined ac-
cording to the 1987 American Rheumatism classification
criteria [19]) who were members of the Early Undifferen-
tiated PolyArthritis (EUPA) Cohort of the University of
Sherbrooke. Adult patients with synovitis affecting at least
three joints for 1 to 12 months were followed longitu-
dinally as previously described [21]. The mean age (SD) of
the patients was 51.1 years (5.0), 23 (70%) of the patients
were female, the median (IQR) disease duration was
1.8 months (1.5 to 2.8) and the median (IQR) Disease
Activity Score in 28 joints (DAS28) was 5.9 (4.8 to 6.5).
Serological assessment comprised erythrocyte sedimenta-
tion rate (ESR), CRP, RF and ACPA, and radiographic as-
sessments were performed using the Sharp/van der Heijde
Score (SHS). Radiographs obtained at baseline and at the
30-month follow-up examination were available. Radio-
graphic progression was determined based on the change
in SHS at 30 months. All radiographs were read in known
time sequence by one or two trained reviewers blinded
to patient characteristics and treatment. At baseline,
all patients were disease-modifying anti-rheumatic drug
(DMARD)–naïve. Patients were treated with the objective
of rapidly attaining a zero swollen joint count. During the
30-month follow-up period, 29 patients (88%) received
conventional DMARD therapy and 5 (15%) received oral
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therapy at the time of the 30-month evaluation.
Cohort B
Cohort B comprised 40 patients with established RA at
the year 3 time point of the Behandel Strategieën (BeSt)
study [22]. The patients’ mean age (SD) was 50.9 years
(12.2), and 30 (75%) of the patients were female. The
median (IQR) DAS28 score was 1.9 (1.5 to 2.6). In the
BeSt study, patients were assigned to one of four treat-
ment strategies: sequential DMARD monotherapy
(group 1), step-up combination therapy (group 2), initial
combination therapy with tapered high-dose prednisone
(group 3) and initial combination therapy with the TNF
inhibitor infliximab (group 4). The patients in our
present 14-3-3η study were selected from among groups
1 through 3. Patients in group 4 were not included,
because, as we have previously reported, 14-3-3η is a
TNF-responsive gene whose levels are modifiable with
TNF inhibitor therapy in both RA and psoriatic arthritis
patients [6,23]. Treatment may therefore have a con-
founding effect on the assessment of 14-3-3η’s asso-
ciation with radiographic progression, even in groups 1,
2 and 3.
Serological measurements for CRP, RF and ACPA were
analysed, and joint assessments performed, using the
SHS as previously described [22,24]. Radiographs were
available for the 3- and 5-year time points of our present
study. Radiographic progression was determined based
on the change in the SHS at year 5.
This study was performed in accordance with the
Declaration of Helsinki, and the study protocol was ap-
proved by the Health Research Ethics Review Board of
the University of Sherbrooke and the Ethics Review
Board of Leiden University. All patients provided their
written informed consent to participate in the study.
Radiographic assessment
To investigate 14-3-3η’s clinical association with radio-
graphic joint damage and joint damage progression for
both the early and established RA cohorts, we compared
the groups according to the presence or absence of joint
damage at the start of the study (SHS <1 or ≥1) and accor-
ding to the presence or absence of radiographic progression
at the end of the follow-up period (ΔSHS <1 or ≥1).
Serum 14-3-3η measurements
Serum 14-3-3η levels were measured using a 14-3-3η
enzyme-linked immunosorbent assay (Augurex Life
Sciences Corp). Serum samples were diluted 1:20 using
the supplied assay dilution buffer. A 100-μl volume of
either the corresponding standard or sample was incu-
bated in a 96-well plate shaker for 2 hours at 500 rpm
and 27°C. Following incubation, the plates were washedfour consecutive times with wash buffer and then incu-
bated with the prediluted horseradish peroxidase–
conjugated antibody for 1 hour at room temperature
without shaking. The plates were washed four additional
times and subsequently incubated with 3,3′,5,5′-tetra-
methylbenzidine substrate for 30 minutes, at which time
the reaction was terminated by the addition of 1 N HCl
stop solution. Serum 14-3-3η levels were quantified
using a four-parameter logistic regression curve gener-
ated against the diluted standards. The accuracy of the
results were evaluated by examining the precision of the
back-calculated concentrations of each of the standards
and the corresponding measurements of three quality
control samples with known 14-3-3η levels within the
linear range of the assay. All clinical samples were run
in duplicate. Samples with levels below the reportable
range were assigned a concentration of 0.0 ng/ml, and
those with levels above the upper limit were defined as
having levels >20 ng/ml. Actual 14-3-3η concentrations
for samples with values >20 ng/ml were determined by
serial dilution and used for statistical analysis.
Statistical analysis of clinical 14-3-3η expression
The Mann–Whitney U test was used to compare me-
dian differences between groups. A two-tailed Student’s
t-test with Welch’s correction was employed to account
for significant variances between groups. Pearson pro-
duct–moment correlations were calculated to examine
the relationship between 14-3-3η and clinical and sero-
logical measurements, including DAS28 and titres of
CRP, RF and ACPA.
Fisher’s exact test was used to compare the association
between 14-3-3η positivity, at various positivity cut
points, of RF or ACPA with radiographic damage status
(SHS <1 or ≥1) and radiographic progression (ΔSHS <1
or ≥1). 14-3-3η positivity cutoffs were defined at the
diagnostic positivity cutoff of ≥0.19 ng/ml, approxi-
mately twice the diagnostic cutoff (0.4 ng/ml) and four
times the diagnostic cutoff (0.8 ng/ml). Univariate re-
gression analyses were performed to identify which clin-
ical and serological markers were associated with joint
damage status and radiographic progression in the two
cohorts. Further regression analyses were performed to
identify variables associated with radiographic damage
status and/or progression by combining only those vari-
ables that had a P-value ≤0.10 in univariate analysis.
The strength of the association is expressed using χ2
likelihood ratios with 95% confidence intervals (CI), to-
gether with the total variance, to inform the primary
outcome (R2).
All statistical analyses were performed using Prism 6
software (GraphPad Software, La Jolla, CA, USA) and
JMP9 software (SAS Institute, Cary, NC, USA). Results
were considered significantly different at P < 0.05.
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A pathophysiologic role for extracellular 14-3-3η
Stimulation of THP-1 cells with recombinant 14-3-3η re-
sulted in an increase in the phosphorylation of ERK and
JNK/SAPK by approximately 87% and 227% above control
at 2 and 5 minutes, respectively (Figure 1A to 1C). In
contrast to TNFα, no phosphorylation of p38MAPK by
14-3-3η was observed at any time point evaluated. These
results suggest that 14-3-3η and TNFα possess both com-
mon and unique signalling effects.
As depicted in Figure 1D and 1E, stimulation of THP-1
cells with 14-3-3η resulted in the dose-dependent induc-
tion of inflammatory transcripts and factors directly linked
to the joint damage process, such as IL-1β, IL-6, MMP-1,
MMP-9 and RANKL. Similar effects were observed with
TNFα when the same concentration was used. Induction
of transcripts by 14-3-3η was evident with concentrations
as little as 1.0 ng/ml across all of the factors tested
(Figure 1E), which corresponds with levels reported in
patients with RA (Table 1). Certain transcripts, such asFigure 1 Extracellular 14-3-3η selectively activates extracellular signa
protein kinase and potentiates inflammatory and joint damage factor
signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). p-MEK, Phospho
stress-activated protein kinase. (B) Equal protein loading. (C) The effects were sp
protein kinase (p38MAPK) by 14-3-3η was not observed. (D) Similarly to tumour
and joint damage factors. IL, Interleukin; GAPDH, Glyceraldehyde 3-phosphate d
of nuclear factor κB ligand. (E) 14-3-3η induced effects observed with 14-3-3η c
arthritis (RA) serum concentrations.IL-1β and MMP-1, were determined to be more sensitive
to stimulation by 14-3-3η, which was evident even as low
as 0.1 ng/ml.
Relationship of 14-3-3η with clinical and serological
measures
Table 2 provides the correlations between the clinical
and serological variables. In both the early and esta-
blished RA cohorts, 14-3-3η titres did not correlate
significantly with DAS28 scores or CRP levels. There
was a modest correlation with RF (r = 0.43, P < 0.01) and
ACPA (r = 0.31, P < 0.05) in the early RA cohort, but not
in the established RA cohort.
14-3-3η serum concentration and its association with
radiographic damage and progression in rheumatoid
arthritis
Twenty (61%) of the thirty-three early RA patients with
30-month follow-up data developed radiographic pro-
gression and twenty (50%) of forty RA patients in thel-regulated kinase and c-Jun N-terminal kinase/stress-activated
s. (A) 14-3-3η leads to the phosphorylation and activation of extracellular
rylated mitogen-activated protein kinase kinase; p-SAPK, Phosphorylated
ecific for ERK and JNK because phosphorylation of p38 mitogen-activated
necrosis factor α (TNFα), 14-3-3η leads to the induction of inflammatory
ehydrogenase; MMP, Matrix metalloproteinase; RANKL, Receptor activator
oncentrations that closely approximated the 14-3-3η median rheumatoid
Table 1 Patient characteristics based on radiographic progression in two cohorts of rheumatoid arthritis patientsa













Patients, n 13 20 – 20 20 –
DAS28 ESR 5.0 (4.4 to 5.7) 6.1 (5.3 to 6.5) 0.04 1.9 (1.4 to 2.3) 1.9 (1.6 to 2.7) 0.56
Mean age (SD), yr 50.9 (5.2) 51.3 (5.0) 0.82 50.3 (10.6) 51.5 (13.9) 0.77
Sex, n (% female) 10 (77%) 13 (65%) – 14 (70%) 16 (80%) –
Baseline SHS 0 (0 to 0) 2.5 (1.0 to 6.8) 0.0002 1.0 (0 to 16) 38.7 (23.2 to 56.8) <0.0001
CRP, mg/L 12.0 (6.0 to 22.5) 12.5 (6.5 to 24.5) 0.82 3.0 (2.0 to 6.0) 8.0 (5.3 to 22.0) 0.001
RF, IU/ml 0 (0 to 160.0) 160.0 (40.0 to 320.0) 0.035 48.0 (2.0 to 68.0) 55.0 (19.5 to 223.8) 0.13
ACPA, U/ml 12 (6.5 to 96.0) 101.0 (14.3 to 194.3) 0.18 59.5 (20.3 to 365.9) 75.1 (20.3 to 440.3) 0.77
Mean 14-3-3η (SD), ng/ml 1.30 (3.51) 6.13 (8.33) 0.03 3.76 (6.92) 4.37 (8.02) 0.79
Median 14-3-3η (IQR), ng/ml 0.09 (0.06 to 12.59) 2.68 (0.12 to 15.94) 0.006 0.28 (0 to 4.54) 1.11 (0.10 to 2.89) 0.16
aACPA, Anticitrullinated protein antibody; SHS, Sharp/van der Heijde score; CRP, C-reactive protein; DAS28 ESR, Disease Activity Score in 28 joints with erythrocyte
sedimentation rate; RA, Rheumatoid arthritis; RF, Rheumatoid factor. P-values were calculated using the Mann–Whitney U test.
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istics of the patients in the two cohorts, who were grouped
according to radiographic progression (ΔSHS <1 or ≥1),
are provided in Table 1. Patients in both groups were
well-matched for age and sex. In the early RA patient
group, the median baseline DAS28 score was higher in
the progression group than in the no-progression group
(6.1 vs. 5.0; P = 0.04), whereas baseline DAS28 scores in
the established RA cohort did not differ significantly bet-
ween the progression and no-progression groups (1.9 vs.
1.9; P = 0.56). Median (IQR) baseline 14-3-3η levels were
significantly higher in early RA patients with radiographic
progression compared with those whose RA did not pro-
gress (2.68 ng/ml (0.12 to 15.94) vs. 0.09 ng/ml (0.06 to
12.59); P = 0.006). 14-3-3η levels were also higher in
established RA patients with radiographic progression.
However, these levels were not significantly differentTable 2 Correlation of 14-3-3η with clinical and serological m
arthritisa












aACPA, Anticitrullinated protein antibody; CRP, C-reactive protein DAS28: Disease Ac
Cohort A is the University of Sherbrooke early rheumatoid arthritis cohort at the ba
cohort of patients with established RA at the year 3 time point (n = 40).(1.11 ng/ml (0.10 to 2.89) vs. 0.28 ng/ml (0 to 4.5);
P = 0.16). The respective scatterplots for 14-3-3η serum
concentrations according to radiographic progression
(ΔSHS <1 or ≥1) are provided in Figure 2.
Univariate analysis revealed that the strength of the
association of radiographic damage at baseline and
radiographic damage progression increased with higher
14-3-3η positivity cut points in both the early and estab-
lished RA cohorts (Table 3). Using the diagnostic cutoff
of ≥0.19 ng/ml, the odds ratio (OR) of radiographic dam-
age progression in early RA was 6.2 (95% CI = 1.3 to 30.2;
P = 0.022), which increased to 10.2 (95% CI = 1.7 to 59.7;
P = 0.006) with cutoffs of ≥0.40 ng/ml and ≥0.80 ng/ml,
respectively. RF positivity was also determined to be asso-
ciated with radiographic progression in the early RA co-
hort, with an OR of 9.1 (95% CI = 1.7 to 47.7; P = 0.008).
In the established RA cohort, the OR of radiographiceasures in two cohorts of patients with rheumatoid
RP RF ACPA








tivity Score in 28 joints; RF: rheumatoid factor. bP < 0.01; cP ≤ 0.05; dP < 0.001.








No Yes No Yes




Figure 2 Scatterplots illustrating serum 14-3-3η concentration
according to radiographic progression of rheumatoid arthritis.
Radiographic progression of rheumatoid arthritis (RA) was defined as
any change in Sharp/van der Heijde score <1 or ≥1 at the end of
the follow-up period (30 months for early RA (n = 33) and 2 years for
established RA (n = 40)). Triangle = patients with no erosion;
Square = patients with erosions; Line = mean levels.
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≥0.40 ng/ml (OR = 4.3 (95% CI = 1.2 to 16.3; P = 0.028)
than at the cutoff of ≥0.19 ng/ml (OR = 2.5 (95% CI = 0.6
to 9.4; P = 0.18). The CRP titre was the only other variable
determined to be associated with radiographic progression
in the established RA cohort (OR = 1.1 (95% CI = 1.0 to
1.4; P = 0.003).
The models presented in Table 4 demonstrate that
14-3-3η positivity adds incrementally to other significant
clinical and serological measures in univariate analysis
with regard to informing radiographic status and progres-
sion. In the early RA cohort, when 14-3-3η positivity (cut-
off set at 0.19 ng/ml) is combined with CRP to inform
radiographic status, the contribution to the total varianceTable 3 Univariate association of clinical and laboratory varia
Variable
Early RA (n = 33)
Baseline damage status Progression
OR (95% CI) P-value OR (95% CI)
DAS28 ESR 1.2 (0.7 to 2.3) 0.485 1.7 (0.9 to 3.6)
Age 1.0 (0.8 to 1.1) 0.505 1.0 (0.9 to 1.2)
Sex 2.8 (0.6 to 13.8) 0.192 1.8 (0.4 to 8.7)
CRP 1.0 (1.0 to 1.1) 0.084 1.0 (1.0 to 1.0)
ACPA + ve 1.1 (0.3 to 4.4) 0.580 2.2 (0.5 to 9.0)
RF + ve 2.5 (0.6 to 11.3) 0.195 9.1 (1.7 to 47.7)
14-3-3η
+ve ≥0.19 ng/ml 4.0 (0.9 to 17.2) 0.057 6.2 (1.3 to 30.2)
+ve ≥0.40 ng/ml 5.5 (1.2 to 24.8) 0.025 10.2 (1.7 to 59.7)
+ve ≥0.80 ng/ml 5.5 (1.2 to 24.8) 0.025 10.2 (1.7 to 59.7)
aACPA, Anticitrullinated protein antibody; CI, Confidence interval; CRP, C-reactive pr
rate; OR, Odds ratio; RA, Rheumatoid arthritis; RF, Rheumatoid factor; +ve, Depende
corresponding P-value ≤0.10 are presented in bold.of the outcome (R2) increases from 0.065 to 0.154. In
established RA, when combined with CRP titres, together
with RF and ACPA positivity, the contribution to total
variance (R2) increases from 0.376 to 0.425. With respect
to radiographic RA progression, when 14-3-3η positivity
(cutoff set at ≥0.40 ng/ml) is combined with DAS28 score
and RF positivity, the contribution to the total variance in
the early RA cohort increases from 0.252 to 0.310. In the
established RA cohort, when 14-3-3η positivity is com-
bined with CRP titres, the contribution to the total vari-
ance increases from 0.167 to 0.262.
Discussion
14-3-3η is one of seven members of the 14-3-3 family
that are preferentially expressed at higher concentrations
in certain tissues, underscoring the importance of spe-
cific isoforms in the regulation of tissue-specific func-
tions [25-27]. Data that we reported in 2007 indicated
that 14-3-3η is expressed at significantly higher levels
than the other isoforms in the synovial fluid of patients
with arthritis and that these levels were three to five
times higher than corresponding levels in the serum of
matched donors, citing the joint as the likely source of
serum 14-3-3η [5]. Since that first report, we have de-
monstrated that 14-3-3η is an RA-specific marker that
complements both RF and ACPA, increasing their diag-
nostic value [6-8]. We also reported a positive asso-
ciation between 14-3-3η and MMPs and suggested that
14-3-3η may have a role in the pathogenesis of RA [28].
To expand upon our understanding of the biological
relevance of extracellular 14-3-3η, we performed in vitro
cell signalling studies to determine if 14-3-3η signals
through the MAPK family, as well as through which
family members. This family was selected because the
transcription factor AP-1, which resides downstream inbles with damage status and radiographic outcomesa
Established RA (n = 40)
Baseline damage status Progression
P-value OR (95% CI) P-value OR (95% CI) P-value
0.094 1.5 (0.5 to 4.9) 0.496 1.4 (0.6 to 3.5) 0.475
0.815 1.1 (1.0 to 1.2) 0.112 1.0 (1.0 to 1.1) 0.763
0.462 1.0 (0.2 to 6.0) 0.660 1.7 (0.4 to 7.3) 0.358
0.906 1.6 (1.1 to 3.1) 0.004 1.1 (1.0 to 1.4) 0.003
0.239 7.7 (1.3 to 45.3) 0.022 2.2 (0.6 to 8.5) 0.214
0.008 10.3 (1.7 to 62.7) 0.010 1.2 (0.3 to 4.5) 0.500
0.022 9.0 (1.5 to 53.9) 0.014 2.5 (0.6 to 9.4) 0.160
0.006 4.4 (0.8 to 25.2) 0.089 4.3 (1.2 to 16.3) 0.028
0.006 7.9 (0.8 to 25.2) 0.044 3.5 (0.9 to 13.0) 0.055
otein; DAS28, Disease Activity Score in 28 joints; ESR, Erythrocyte sedimentation
nt variable increase for increase in independent variable. Variables with
Table 4 Multivariate analyses indicating contribution of 14-3-3η to total variance in radiographic damage status and
radiographic progressiona
Cohort Outcome Without 14-3-3η
With 14-3-3η
≥0.2 ng/ml ≥0.4 ng/ml ≥0.8 ng/ml
Early RA Joint damage status Model LR 2.99 7.06 8.54 8.54
p 0.084 0.029 0.014 0.014
R2 0.065 0.154 0.187 0.187
Radiographic progression Model LR 11.16 12.27 13.72 13.72
P 0.004 0.007 0.003 0.003
R2 0.252 0.273 0.310 0.310
Established RA Joint damage status Model LR 12.35 13.94 12.36 12.76
P 0.006 0.008 0.015 0.013
R2 0.376 0.425 0.377 0.389
Radiographic progression Model LR 8.78 9.71 13.78 13.13
P 0.003 0.008 0.001 0.001
R2 0.167 0.185 0.262 0.250
aLR, Likelihood ratio; RA, Rheumatoid arthritis.
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expression. The data produced in this study indicate that
stimulation of cells with 14-3-3η, similarly to TNFα, re-
sults in the phosphorylation of both ERK and JNK/SAPK
in a time-dependent manner. However, unlike TNFα,
14-3-3η had no impact on p38MAPK phosphorylation.
The differential effects of 14-3-3η in relation to TNFα
on the activation of MAPK family members indicates
that these two ligands, which are present in the serum of
patients with RA, are likely to signal by divergent mech-
anisms. Phosphorylation of these two MAPK members,
ERK and JNK/SAPK, together with the finding that 14-
3-3η is present in the serum of 60% to 82% of early RA
patients [8], is consistent with the observations repor-
ted by de Launay et al.: that ERK and JNK, but not
p38MAPK, are preferentially phosphorylated in early RA
[19]. On the basis of these findings, we propose that the
relationship between 14-3-3η expression and the phos-
phorylation status of the MAPK family members, espe-
cially in early RA, be investigated in human synovial
tissue.
It is well-established that phosphorylation of both ERK
and JNK/SAPK at the TXY motif within the activation
loop of these kinases is reflective of their activation. In
turn, these MAPKs directly and/or indirectly phospho-
rylate the transcription factor c-Jun. Phosphorylation of
c-Jun results in its association with c-fos, the formation
of the AP-1 transcription complex and the transactivation
or switching-on of genes containing the AP-1 binding site
[29]. In this head-to-head analysis, we demonstrate that
14-3-3η at a concentration similar to that of TNFα, is
capable of inducing genes that have been described in the
literature as being TNFα-responsive. Our 14-3-3η dose es-
calation studies demonstrate that these TNFα-responsivegenes are highly sensitive to 14-3-3η stimulation and can
be induced with as little as 1.0 ng/ml, a 14-3-3η con-
centration that approximates median concentrations mea-
sured in the serum of RA patients [6-8]. On the basis of
these in vitro findings, it is evident that 14-3-3η may play
a role in perpetuating inflammation through the induction
of factors such as IL-6 and by exacerbating joint des-
truction via MMPs and RANKL. Examining 14-3-3η’s
expression in relation to clinical outcomes in RA patients
will be of utmost importance in understanding how 14-3-
3η serum expression used as a diagnostic test can assist
clinicians with patient management, to further substanti-
ate its relevance to the pathophysiology of RA and to gain
a better understanding of how 14-3-3η biomarker expres-
sion can be aligned with the advancement of a 14-3-3η-
targeted therapy to identify the subset of patients who are
more likely to respond to such an approach.
High levels of other 14-3-3 isoforms have been associ-
ated with more severe disease or worse outcomes in many
patient groups, including, but not limited to, carcinoma
[30-33], Creutzfeldt-Jakob disease [34], Alzheimer’s dis-
ease [35], multiple sclerosis [36], infarction [37] and HIV
[38]. Analysis of serum 14-3-3η expression in relation to
joint damage and progression revealed significantly higher
levels of 14-3-3η in patients who already had radiographic
evidence of damage at study baseline, as well as in those
who developed progression by the end of the follow-up
period. Amongst other laboratory variables tested, none
were significantly associated with radiographic status at
baseline in the early RA cohort and only RF was signifi-
cantly associated with radiographic progression. Neverthe-
less, 14-3-3η contributed to the variance of a regression
model for radiographic progression (R2) that included RF.
The association of 14-3-3η with radiographic status and
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the early RA cohort, but DAS28 control was already very
well-established by year 3 in the majority of patients in the
BeSt cohort (mean DAS28 = 1.9). Of the three laboratory
variables examined—CRP, RF, and ACPA—only CRP was
associated with radiographic progression. 14-3-3η contri-
buted to the variance of a regression model for radio-
graphic progression that included CRP.
In this study, we observed that serum 14-3-3η did not
correlate with disease activity (DAS28) or with titres of
CRP. We noted a modest correlation with ACPA and RF
in the early RA cohort, but not in the established RA
cohort. These findings indicate that 14-3-3η may act in-
dependently of these measures, which is one of the key
requirements proposed by the Outcome Measures in
Rheumatology (OMERACT) soluble biomarker working
group for a biomarker reflecting joint damage [39]. The
OMERACT guidelines state that, in order to be useful at
informing structural damage endpoints, a marker should
be independent of other commonly available variables
associated with radiographic progression and should
complement them in predictive models. Regression ana-
lyses revealed that 14-3-3η added incrementally to the
predictive power of the model. On the basis of these
findings, a prospective study designed to examine 14-3-
3η’s capacity as an independent predictor of radiographic
damage status and progression is underway.
As with proof-of-concept studies, one of the main li-
mitations of the present study is the small sample size
for both RA cohorts. In addition, relatively few patients
demonstrated substantial joint damage progression. The
results of this study are being used in the design of lar-
ger studies to formally investigate the merits of 14-3-3η
in marking joint damage and predicting radiographic
progression in combination with other clinical variables.
In addition, we have previously shown that 14-3-3η is
modifiable by both anti-TNF and standard DMARD
therapies [40,41]. Confounding by treatment is a signifi-
cant limitation of studies in which the predictive role of
biomarkers is assessed when only baseline biosamples
are available. It is to be anticipated that levels of 14-3-3η
are likely to change in both cohorts when treatment
changes are driven by DAS28 targets, which will limit
the predictive capacity of biosample data that are avail-
able only at baseline. This was particularly noteworthy
in a previous report of BeSt study patients in which
baseline levels of acute-phase reactants, RF and ACPA
were not shown to be predictive of radiographic progres-
sion in the two patient groups undergoing intensive
therapy. However, RF and ACPA were predictive in
patients being treated with monotherapy or combination
therapy with standard DMARDs [24]. Consequently,
future studies should assess biosamples at multiple time
points.Conclusions
In our present study, we demonstrate that extracellular 14-
3-3η is an activator of ERK and JNK, but not p38MAPK.
These effects are comparable to, yet distinct from, TNFα.
At concentrations present in the serum of RA patients,
stimulation of monocytes with soluble 14-3-3η results in
the induction of genes that perpetuate inflammation and
drive joint damage. Our clinical biomarker results reveal
that 14-3-3η expression is higher in the serum of patients
with radiographic evidence of damage and progression.
The alignment between the in vitro findings and the clin-
ical biomarker expression profile provide a strong rationale
for investigating 14-3-3η as both a marker of radiographic
outcome and possibly a new therapeutic target.
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